A corporate venture/life science investment arm of a global life science, and medical equipment manufacturer invests from an evergreen fund and prefers to invest at company formation/seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.

The firm prefers to invest in teams with a strong track record but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of the parent company to help companies with regulatory affairs, market access, and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Canada-based venture capital firm focuses on investments in three main sectors: Biopharmaceutical, Healthcare Platform & Services, and Technology. The firm provides initial investments at USD 3-5 million, and it will also reserve a further amount for follow-on financing and supports the startups in strategic partnerships. The firm is interested in pre-clinical to clinical-stage biotech companies. The firm invests primarily in North America but also opens to invest in Europe or China.

The firm is looking for new opportunities in the life science space, including therapeutics, diagnostics, and healthcare platforms. The firm’s investments to date have included companies developing in cell therapy, oncology, neuroscience, and drug-discovery platform. The firm is opportunistic in terms of sector, subsectors, and indications. The firm will also consider orphan drugs. Within medical devices and digital health, the firm will only consider companies that already have a USD 10 million minimum revenue. The firm will only co-invest and will prefer to co-invest with well-known lead investors.

The firm does not have specific requirements on companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in Western Europe seeks to make 4-5 investments over the next 6 to 12 months. The firm could lead any investment up to €15M but will also look for syndicate participation in bigger rounds. Allocations are in the form of equity. Allocations are typically made at the venture stage of development but are open to consider Seed through IPO rounds. The firm focuses on companies based in Europe, but also considers companies in Israel and USA.

The firm will look at a broad spectrum of products and services within the life science space. While the firm has traditionally not considered therapeutics, the firm is now open to making investments in this space. The firm is most interested in medical devices and diagnostics including in-vitro diagnostics, and also looks into digital health. They will look at any stage of development within those categories and long as the product or service shows substantial market potential and have proof of concept.

The firm is willing to work with all types of management teams as long as entrepreneurs/founders have a solid knowledge in the industry. A board seat is required for all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen venture fund based in the USA is a flexible investor; the firm’s initial allocations vary depending on the company’s developmental stage, from $150,000 to several million dollars. The firm is open to being a lead investor, and will consider opportunities globally. The firm is open to investing in both privately held companies and publicly traded companies.

The firm invests in the therapeutics sector. The firm only invests in companies with assets that are at the clinical phase of development, and which are based on solidly vetted science. The firm is agnostic in therapeutic indications and will consider opportunities in any area of medicine.

The firm likes to invest as part of a syndicate in science at a US or OUS company that will create a value inflection from a well executed study. The firm has a flexible approach to management teams and may be a more hands-on investor if the management team has limited business experience. The firm prefers to invest in companies that already have an exit plan in mind.  The firm requires a high level of transparency from portfolio companies, and guides portfolio companies in planning studies that will create real value inflection points for the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.